Laurie Ann Moennich

Laurie Ann Moennich

Auto-generated profile, based on publicly available information

Laurie Ann Moennich

Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
DPDivyang Patel
Divyang Patel
KTKevin M. Trulock
Kevin M. Trulock
STSaleem Toro
Saleem Toro
AGAdam Grimaldi
Adam Grimaldi
MGMatthew Gonzalez
Matthew Gonzalez
JRJohn Rickard
John Rickard

1 September 2021 in Resuscitation Plus
Verified
Journal Article
Open access
AKAnirudh Kumar
Anirudh Kumar
LZLeon Zhou
Leon Zhou
CHChetan P. Huded
Chetan P. Huded
LMLaurie Ann Moennich
Laurie Ann Moennich
VMVenu Menon
Venu Menon
UKUmesh N. Khot
Umesh N. Khot
Cardiac arrest (CA) complicating ST-elevation myocardial infarction (STEMI) is associated with a disproportionately higher risk of mortality. We described the contemporary presentation, management, and outcomes of CA patients in the era of primary percutaneous coronary intervention (PCI). We reviewed 1,272 consecutive STEMI patients who underwent PCI between 1/1/2011-12/31/2016 and compared characteristics and outcomes between non-CA (N = 1,124) and CA patients (N = 148), defined per NCDR definitions as pulseless arrest requiring cardiopulmonary resuscitation and/or defibrillation within 24-hr of PCI. Male gender, cerebrovascular disease, chronic kidney disease, in-hospital STEMI, left main or left anterior descending culprit vessel, and initial TIMI 0 or 1 flow were independent predictors for CA. CA patients had longer door-to-balloon-time (106 [83,139] vs. 97 [74,121] minutes, p = 0.003) and greater incidence of cardiogenic shock (48.0% vs. 5.9%, p < 0.001), major bleeding (25.0% vs. 9.4%, p < 0.001), and 30-day mortality (16.2% vs. 4.1%, p < 0.001). Risk score for 30-day mortality based on presenting characteristics provided excellent prognostic accuracy (area under the curve = 0.902). However, over long-term follow-up of 4.5 ± 2.4 years among hospital survivors, CA did not portend any additional mortality risk (HR: 1.01, 95% CI: 0.56–1.82, p = 0.97). In a contemporary cohort of STEMI patients undergoing primary PCI, CA occurs in >10% of patients and is an important mechanism of mortality in patients with in-hospital STEMI. While CA is associated with adverse outcomes, it carries no additional risk of long-term mortality among survivors highlighting the need for strategies to improve the in-hospital care of STEMI patients with CA.

6 September 2021 in Heart
Verified
Journal Article
Closed access
PDF file
DPDivyang Patel
Divyang Patel
AKAnirudh Kumar
Anirudh Kumar
LMLaurie Ann Moennich
Laurie Ann Moennich
KTKevin Trulock
Kevin Trulock
DNDavid M Nemer
David M Nemer
JRJohn Rickard
John Rickard
Introduction Chemotherapy-induced cardiomyopathy has been increasingly recognised as patients are living longer with more effective treatments for their malignancies. Anthracyclines are known to cause left ventricular (LV) dysfunction. While heart failure medications are frequently used, some patients may need consideration for device-based therapies such as cardiac resynchronisation therapy (CRT). However, the role of CRT in anthracycline-induced cardiomyopathy (AIC) is not well understood. Methods We performed a retrospective review of all patients undergoing CRT implantation at our centre from 2003 to 2019 with a diagnosis of AIC. The LV remodelling and survival outcomes of this population were obtained and then compared with consecutive patients with other aetiologies of non-ischaemic cardiomyopathy (NICM). Results A total of 34 patients underwent CRT implantation with a diagnosis of AIC with a mean age of 60.5±12.7 years, left ventricular ejection fraction (LVEF) of 21.7%±7.4%, and 11.3±7.5 years and 10.2±7.4 years from cancer diagnosis and last anthracycline exposure, respectively. At 9.6±8.1 months after CRT implantation, there was an increase of LVEF from 21.8%±7.6% to 30.4%±13.0% (p<0.001). Patients whose LVEF increased by at least 10% post-CRT implant (42.5% of cohort) survived significantly longer than patients who failed to improve their LVEF by that amount (p=0.01). A propensity matched analysis between patients with AIC and 369 consecutive patients with other aetiologies of NICM who underwent CRT implantation during the same period revealed no significant differences in improvement in LVEF or long-term survival. Conclusions Patients with AIC undergo LV remodelling with CRT at rates similar to other aetiologies of NICM. Furthermore, AIC post-CRT responders have a favourable long-term mortality compared with non-responders.

10 October 2014 in Vascular Medicine
Verified
Journal Article
Open access
LMLaurie Ann Moennich
Laurie Ann Moennich
TMTara M Mastracci
Tara M Mastracci
Abdominal aortic aneurysm is a silent but often fatal disease. AAA is most common in older people, with both modifiable (such as smoking) and hereditary (family history of AAA) risk factors influencing disease development. Screening for AAA can aid in the early diagnosis and treatment of the disease, reducing complications and death amongst those affected. Advancements in screening techniques, surgical innovations, and graft development strive to further improve patient outcomes and disease management.

1 March 2019 in JACC
Verified
Journal Article
Closed access
DPDivyang Patel
Divyang Patel
KTKevin Trulock
Kevin Trulock
STSaleem Toro
Saleem Toro
LMLaurie Ann Moennich
Laurie Ann Moennich
EKErich Kiehl
Erich Kiehl
JRJohn Rickard
John Rickard

1 May 2021 in JACC
Verified
Journal Article
Closed access
LMLaurie Ann Moennich
Laurie Ann Moennich
AKAnirudh Kumar
Anirudh Kumar
DPDivyang Patel
Divyang Patel
KTKhaldoun Tarakji
Khaldoun Tarakji